DK1446128T3 - Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling - Google Patents

Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling

Info

Publication number
DK1446128T3
DK1446128T3 DK02738962T DK02738962T DK1446128T3 DK 1446128 T3 DK1446128 T3 DK 1446128T3 DK 02738962 T DK02738962 T DK 02738962T DK 02738962 T DK02738962 T DK 02738962T DK 1446128 T3 DK1446128 T3 DK 1446128T3
Authority
DK
Denmark
Prior art keywords
component
compounds
aforementioned
hormone replacement
formula
Prior art date
Application number
DK02738962T
Other languages
Danish (da)
English (en)
Inventor
Christian Franz Holinka
Bennink Herman Jan Ti Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of DK1446128T3 publication Critical patent/DK1446128T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02738962T 2001-11-15 2002-05-23 Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling DK1446128T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01204377 2001-11-15
EP02075695 2002-02-21
PCT/NL2002/000332 WO2003041718A1 (fr) 2001-11-15 2002-05-23 Utilisation de composes oestrogenes combines a des composes progestogenes en therapie de substitution hormonale

Publications (1)

Publication Number Publication Date
DK1446128T3 true DK1446128T3 (da) 2007-04-02

Family

ID=26077031

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02738962T DK1446128T3 (da) 2001-11-15 2002-05-23 Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling

Country Status (10)

Country Link
US (1) US8026228B2 (fr)
EP (1) EP1446128B1 (fr)
AT (1) ATE347365T1 (fr)
CA (1) CA2467222C (fr)
CY (1) CY1105957T1 (fr)
DE (1) DE60216630T2 (fr)
DK (1) DK1446128T3 (fr)
ES (1) ES2278925T3 (fr)
PT (1) PT1446128E (fr)
WO (1) WO2003041718A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1390042B1 (fr) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
DK1562976T3 (da) 2002-11-08 2010-08-16 Pantarhei Bioscience Bv Syntese af estetrol via estron-afledte steroider
JP2006526025A (ja) * 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
DE602004018921D1 (de) * 2003-06-25 2009-02-26 Bayer Schering Pharma Ag D dienogest
US7498322B2 (en) * 2004-03-12 2009-03-03 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
WO2006058298A2 (fr) * 2004-11-29 2006-06-01 Entremed, Inc. Procede d'administration d'agents anti-angiogeniques, et methode de traitement d'une maladie utilisant lesdits agents
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
WO2007109312A2 (fr) * 2006-03-20 2007-09-27 Entremed, Inc. 2-méthoxyestradiol présentant une activité anti-arthritique pouvant modifier l'évolution de la maladie
WO2008019048A1 (fr) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Utilisation d'inhibiteurs d'aromatase pour amincir l'endomètre ou traiter la ménorragie
CN101583363B (zh) * 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
US20080234243A1 (en) * 2007-01-31 2008-09-25 Lavallee Theresa M Method of treating amyloidosis mediated diseases
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
US9446051B2 (en) * 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
WO2011049948A2 (fr) 2009-10-19 2011-04-28 The Population Council, Inc. Neuroprotection et réparation de la myéline au moyen de la nestorone®
SG195121A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013034780A2 (fr) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Procédé de préparation de l'estétrol et de composés analogues
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3046928B1 (fr) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Procédé de préparation d'estetrol
NO3079671T3 (fr) 2013-12-12 2018-03-24
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
MD3310333T2 (ro) * 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
CN116077454A (zh) * 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
DK3781171T3 (da) * 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
AU2022397887A1 (en) * 2021-11-29 2024-05-16 Estetra Srl Compositions for preventing or treating skin aging
US12233074B2 (en) 2022-02-10 2025-02-25 Estetra Srl Contraceptive methods with improved pearl index
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336434A1 (de) * 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) * 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (fr) 1994-08-04 1996-02-15 Biex, Inc. Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
WO1998058657A1 (fr) 1997-06-20 1998-12-30 Akzo Nobel N.V. Antagoniste de gonadoliberine
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
EP1171091A1 (fr) 1999-04-16 2002-01-16 Jenapharm GmbH & Co. KG Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones
US7273932B1 (en) 1999-05-28 2007-09-25 The University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
AU5984701A (en) 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (fr) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif

Also Published As

Publication number Publication date
US8026228B2 (en) 2011-09-27
EP1446128B1 (fr) 2006-12-06
CA2467222C (fr) 2010-06-08
ATE347365T1 (de) 2006-12-15
CY1105957T1 (el) 2011-04-06
CA2467222A1 (fr) 2003-05-22
PT1446128E (pt) 2007-03-30
US20050070488A1 (en) 2005-03-31
DE60216630T2 (de) 2007-09-20
EP1446128A1 (fr) 2004-08-18
DE60216630D1 (de) 2007-01-18
WO2003041718A1 (fr) 2003-05-22
ES2278925T3 (es) 2007-08-16

Similar Documents

Publication Publication Date Title
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
WO2002094275A8 (fr) Utilisation de composes d'oestrogene pour accroitre la libido chez les femmes
DK1390040T3 (da) Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
CY1108093T1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
SI1624878T1 (sl) Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine
MXPA03001072A (es) El uso de bencilidenaminoguanidinas e hidroxiguanidinas como ligandos de receptor de melanocortina.
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
NO950275L (no) Kombinasjonsbehandling for osteoporose
SI1511496T1 (sl) Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
WO2008085038A3 (fr) Méthode de traitement ou prévention de la stérilité d'un mammifère féminin et trousse pharmaceutique associée
PT1272481E (pt) 4-trifluorometil-2h-benzopiranos antiestrogenicos com accao estrogenica selectiva
MXPA02001571A (es) Metodo de tratamiento para el cancer.
WO2004006936A8 (fr) Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
TW200635942A (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceurical preparations that contain the latter
NZ512981A (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
MY129431A (en) Prodrugs to d-prolines
DE50110892D1 (de) 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
PE20000330A1 (es) Nuevo kit anticonceptivo
WO2004093852A3 (fr) Traitement de maladie liee a l'angiotensine ii
ATE275576T1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen